Drugs / BI 3000202
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07774325 | Sep → Oct 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07486102 | May 2026 → Feb 2027 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07273474 | Dec 2025 → Mar 2026 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07215260 | Nov → Dec 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06878365 | Jul 2025 → Dec 2026 expected | type 1 interferonopathy | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06327256 | Apr → Sep 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05945888 | Jul → Nov 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07409181 | Apr 2026 → Feb 2029 expected | systemic lupus erythematosus | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3000202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05945888 ↗ |
| Route | Oral | “was administered orally with 240 mL of water” NCT05945888 ↗ |